Congresos

← vista completa

Publicado el 1 de junio de 2002 | http://doi.org/10.5867/medwave.2002.05.603

Hiperglicemia postprandial, factor emergente de riesgo cardiovascular en la diabetes tipo 2 (2)

Postprandial hyperglycemia, an emerging cardiovascular risk factor in Type 2 (2)

Ele Ferrannini

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Ele Ferrannini

Università di Pisa, Italia

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Ferrannini E. Postprandial hyperglycemia, an emerging cardiovascular risk factor in Type 2 (2). Medwave 2002;2(05):e603 doi: 10.5867/medwave.2002.05.603

Publicación 01/06/2002

Métricas del artículo

Artículo no tiene métricas.

Notas

Referencias

  1. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. Lancet 1999 Aug 21;354(9179):617-21. | CrossRef
  2. DECODE Study Group, Arch Intern Med 2001;161:397-404.
  3. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. DiabetologÃa 1996 Dec;39(12):1577-83. | CrossRef | PubMed
  4. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, et al Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians”. N Eng J Med 1993 Dec 30;329(27):1988-92. | CrossRef | PubMed
  5. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989;257:E241-246.
  6. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. “Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes”, Diabetes 1988 Jun;37(6):736-44. | CrossRef | PubMed
  7. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48:99-105
  8. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995 Nov; 44(11):1249-58. | CrossRef | PubMed
  9. Guiot Y, Sempoux C, Moulin P, Rahier J. No decrease of the beta-cell mass in type 2 diabetic patients. Diabetes 2001 Feb;50 Suppl 1:S188. | CrossRef
  10. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 1984;7:491-502.
  11. Stumvoll M, Fritsche A, Stefan N, Häring H. A 60 minute hyperglycemic clamp is sufficient to assess both phases of insulin secretion. Horm Metab Res 2000;32:230-232. | CrossRef | PubMed
  12. Bagdade JD, Bierman EL, Porte D Jr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967;46:1549-1557. | CrossRef | PubMed